GVL

Graft-versus-host disease (GvHD) is a medical condition that can occur after an allogeneic tissue transplant. It is a complication that arises when the donor cells attack the recipient's body cells as they perceive them as foreign. This condition is common in stem cell or bone marrow transplants.

Types of Graft-versus-host disease

There are two types of GvHD: acute and chronic.

Acute GvHD usually develops within the first six months after the transplant. It primarily affects the skin, liver, and gastrointestinal tract.

Chronic GvHD usually develops after the first three months and can last for a lifetime. It can affect many organs and tissues, including the skin, mouth, eyes, liver, and lungs.

Symptoms

The symptoms of GvHD depend on the type and severity of the condition. They may include:

• Skin rashes or changes in skin color
• Nausea, vomiting, or diarrhea
• Loss of appetite or weight loss
• Jaundice or yellowing of the skin and eyes
• Dry mouth or eyes
• Shortness of breath or difficulty breathing

Diagnosis

GvHD is diagnosed based on the patient's symptoms and medical history. The doctor may also perform a physical examination and order tests such as blood tests, imaging tests, and biopsies.

Treatment

The treatment for GvHD aims to suppress the immune response and reduce inflammation. This may involve medications such as corticosteroids and other immunosuppressive drugs. In severe cases, additional treatments such as photopheresis or extracorporeal photopheresis (ECP) may be required.

Prevention

Prevention strategies for GvHD include using immunosuppressive drugs and performing a careful donor selection. The risk of GvHD can also be reduced by removing T cells from the donor graft.

See also

• Transplant rejection
• Immunosuppressive drugs
• Photopheresis

GVL Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.